Author:
Taheri Mohammad,Sadeghi Ahmad,Gharebaghi Alireza,Ghiasian Masoud,Eslami Solat,Khalilian Sheyda,Sayad Arezou,Ghafouri-Fard Soudeh
Abstract
AbstractNeuromyelitis optica spectrum disorder (NMOSD) is an immune-related demyelinating defect. Long non-coding RNAs (lncRNAs) might influence the pathobiology and progression of NMOSD. The current study assessed expression level of NEAT1, PANDAR, MEG3 and TUG1 lncRNAs in the peripheral blood of NMOSD patients compared with healthy individuals. All mentioned lncRNAs were shown to be over-expressed in total NMOSD cases, male NMOSD cases and female NMOSD cases compared with the matching control subgroups. MEG3 had the most robust over-expression in patients subgroups compared with normal subjects. There was no noteworthy difference in the expression of any of lncRNAs between female and male patients. MEG3 had an ideal performance in the differentiation of NMOSD cases from healthy persons (Sensitivity and specificity values = 100%). Other lncRNAs could also efficiently separate NMOSD cases from control subjects (AUC values = 0.97, 0.89 and 0.88 for PANDAR, NEAT1 and TUG1, respectively). Cumulatively, NEAT1, PANDAR, MEG3 and TUG1 lncRNAs can be considered as appropriate disease markers for NMOSD.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. You, Y.-F. et al. TREM2 deficiency inhibits microglial activation and aggravates demyelinating injury in neuromyelitis optica spectrum disorder. J. Neuroinflamm. 20, 89 (2023).
2. Etemadifar, M. et al. Non-infectious meningitis and CNS demyelinating diseases: A conceptual review. Rev. Neurol. (2023).
3. Costa, V. G. C., Espírito-Santo Araújo, S., Alves-Leon, S. V. & Gomes, F. C. A. Central nervous system demyelinating diseases: Glial cells at the hub of pathology. Front. Immunol. 14, 11355 (2023).
4. Joseph, J. et al. Relevance of bright spotty lesions in neuromyelitis optica spectrum disorders (NMOSD): A case series. Egypt. J. Neurol. Psychiatry Neurosurg. 58, 165 (2022).
5. Jiang, W. et al. Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data. Neurol. Sci. 44, 1–11 (2023).